Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 3%

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) traded up 3% during trading on Wednesday . The stock traded as high as $3.09 and last traded at $3.05. 403,199 shares changed hands during trading, a decline of 85% from the average session volume of 2,666,752 shares. The stock had previously closed at $2.96.

Analysts Set New Price Targets

Several research analysts have recently issued reports on TSHA shares. Piper Sandler started coverage on Taysha Gene Therapies in a research note on Tuesday. They set an "overweight" rating and a $9.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Needham & Company LLC upped their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Wednesday, March 20th. Canaccord Genuity Group reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Finally, Chardan Capital boosted their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, March 21st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $6.88.

Taysha Gene Therapies Stock Performance

The company has a market capitalization of $587.24 million, a PE ratio of -4.69 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08. The company has a 50 day moving average price of $2.41 and a 200 day moving average price of $2.11.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in the company. Swiss National Bank raised its stake in shares of Taysha Gene Therapies by 9.3% during the first quarter. Swiss National Bank now owns 41,000 shares of the company's stock valued at $267,000 after purchasing an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Taysha Gene Therapies by 85.1% during the 1st quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company's stock worth $2,868,000 after acquiring an additional 202,245 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company's stock valued at $6,599,000 after buying an additional 128,517 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Taysha Gene Therapies during the 1st quarter valued at about $1,633,000. Finally, UBS Group AG lifted its holdings in shares of Taysha Gene Therapies by 33.2% during the 1st quarter. UBS Group AG now owns 67,980 shares of the company's stock valued at $443,000 after buying an additional 16,944 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.